| Market Cap | 35.60M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -5.02M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 44.00% |
| Sales | 72.07k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 27.00% |
| Dividend | N/A | Price/Book | 10.32 | EPS next 5Y | - | 52W High Chg | -15.00% |
| Recommedations | - | Quick Ratio | 0.27 | Shares Outstanding | 157.18M | 52W Low Chg | 147.00% |
| Insider Own | 2.14% | ROA | -136.72% | Shares Float | 156.38M | Beta | 0.41 |
| Inst Own | - | ROE | -2,972.60% | Shares Shorted/Prior | -/- | Price | 0.23 |
| Gross Margin | 90.64% | Profit Margin | - | Avg. Volume | 47,635 | Target Price | - |
| Oper. Margin | -4,509.58% | Earnings Date | Nov 27 | Volume | 23,300 | Change | -0.26% |
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients. Ventripoint Diagnostics Ltd. is headquartered in Toronto, Canada.